KR101781255B1 - 키나아제 저해제로서의 이미다조[1,2-b]피리다진 유도체 - Google Patents

키나아제 저해제로서의 이미다조[1,2-b]피리다진 유도체 Download PDF

Info

Publication number
KR101781255B1
KR101781255B1 KR1020147033351A KR20147033351A KR101781255B1 KR 101781255 B1 KR101781255 B1 KR 101781255B1 KR 1020147033351 A KR1020147033351 A KR 1020147033351A KR 20147033351 A KR20147033351 A KR 20147033351A KR 101781255 B1 KR101781255 B1 KR 101781255B1
Authority
KR
South Korea
Prior art keywords
group
amino
compound
imidazo
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147033351A
Other languages
English (en)
Korean (ko)
Other versions
KR20150014942A (ko
Inventor
야스유키 다케다
겐지 요시카와
요시코 가고시마
유코 야마모토
료이치 다나카
유이치 도미나가
마사키 기가
요시토 하마다
Original Assignee
다이이찌 산쿄 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이이찌 산쿄 가부시키가이샤 filed Critical 다이이찌 산쿄 가부시키가이샤
Publication of KR20150014942A publication Critical patent/KR20150014942A/ko
Application granted granted Critical
Publication of KR101781255B1 publication Critical patent/KR101781255B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020147033351A 2012-06-04 2013-06-03 키나아제 저해제로서의 이미다조[1,2-b]피리다진 유도체 Active KR101781255B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012127079 2012-06-04
JPJP-P-2012-127079 2012-06-04
PCT/JP2013/065328 WO2013183578A1 (ja) 2012-06-04 2013-06-03 キナーゼ阻害剤としてのイミダゾ[１，２－ｂ]ピリダジン誘導体

Publications (2)

Publication Number Publication Date
KR20150014942A KR20150014942A (ko) 2015-02-09
KR101781255B1 true KR101781255B1 (ko) 2017-09-22

Family

ID=49711970

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147033351A Active KR101781255B1 (ko) 2012-06-04 2013-06-03 키나아제 저해제로서의 이미다조[1,2-b]피리다진 유도체

Country Status (32)

Country Link
US (2) US9187489B2 (https=)
EP (1) EP2857404B1 (https=)
JP (1) JP5814467B2 (https=)
KR (1) KR101781255B1 (https=)
CN (1) CN104520300B (https=)
AU (1) AU2013272701B2 (https=)
BR (1) BR112014029851B1 (https=)
CA (1) CA2874819C (https=)
CO (1) CO7160119A2 (https=)
CY (1) CY1119607T1 (https=)
DK (1) DK2857404T3 (https=)
ES (1) ES2648228T3 (https=)
HR (1) HRP20171724T1 (https=)
HU (1) HUE037221T2 (https=)
IL (1) IL236075A (https=)
IN (1) IN2014MN02497A (https=)
LT (1) LT2857404T (https=)
MX (1) MX357021B (https=)
MY (1) MY170326A (https=)
NO (1) NO2857404T3 (https=)
NZ (1) NZ702574A (https=)
PH (1) PH12014502721A1 (https=)
PL (1) PL2857404T3 (https=)
PT (1) PT2857404T (https=)
RS (1) RS56625B1 (https=)
RU (1) RU2635917C2 (https=)
SG (1) SG11201408052WA (https=)
SI (1) SI2857404T1 (https=)
SM (1) SMT201700539T1 (https=)
TW (1) TWI585088B (https=)
WO (1) WO2013183578A1 (https=)
ZA (1) ZA201408843B (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2350075E (pt) 2008-09-22 2014-06-09 Array Biopharma Inc Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase
AR074052A1 (es) 2008-10-22 2010-12-22 Array Biopharma Inc Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
NZ604708A (en) 2010-05-20 2015-05-29 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
AU2013268400B2 (en) 2012-05-30 2017-07-13 Nippon Shinyaku Co., Ltd. Aromatic heterocyclic derivative and pharmaceutical
EP3129376B1 (en) * 2014-03-27 2018-12-26 Janssen Pharmaceutica NV Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4h-pyrazolo[1,5-a][1,4]diazepine derivatives as ros1 inhibitors
CN106132967B (zh) * 2014-03-27 2019-05-28 詹森药业有限公司 作为ros1抑制剂的化合物
IL248408B (en) * 2014-04-25 2022-06-01 Exelixis Inc A method for treating adenocarcinoma of the lungs
HUE061448T2 (hu) 2014-11-16 2023-07-28 Array Biopharma Inc (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid-hidrogénszulfát kristályos formája
WO2016196671A1 (en) 2015-06-01 2016-12-08 Loxo Oncology, Inc. Methods of diagnosing and treating cancer
EA201890086A1 (ru) 2015-06-18 2018-06-29 Сефалон, Инк. 1,4-замещенные производные пиперидина
ES2849951T3 (es) 2015-06-18 2021-08-24 89Bio Ltd Derivados de piperidina 4-bencil y 4-benzoil sustituidos
BR112018000808A2 (pt) 2015-07-16 2018-09-04 Array Biopharma Inc compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
CN108697708A (zh) 2015-10-26 2018-10-23 洛克索肿瘤学股份有限公司 Trk抑制剂抗性癌症中的点突变以及与此相关的方法
CN106854174A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种4位取代哌啶衍生物的制备方法
ES2987474T3 (es) 2016-04-04 2024-11-15 Loxo Oncology Inc Formulaciones líquidas de (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-IL)-pirazolo[1,5-A]pirimidin-3-IL)-3-hidroxipirrolidina-1-carboxamida
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
RS65988B1 (sr) 2016-04-04 2024-10-31 Loxo Oncology Inc Postupak lečenja pedijatrijskih karcinoma
ES2836222T3 (es) 2016-05-18 2021-06-24 Loxo Oncology Inc Preparación de (S)-N-(5-((R)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
CN107400082A (zh) * 2016-05-19 2017-11-28 湖南华腾制药有限公司 一种取代哌啶衍生物的制备方法
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
RS64354B1 (sr) 2017-03-14 2023-08-31 Daiichi Sankyo Co Ltd Postupak za proizvodnju derivata 3, 6-disupstituisanog imidazo[1, 2-b]piridazina
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
US20190247398A1 (en) 2017-10-26 2019-08-15 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
CN109748902B (zh) * 2017-11-02 2020-11-06 杭州科巢生物科技有限公司 一种盐酸安罗替尼的制备方法
WO2019107671A1 (ko) * 2017-11-29 2019-06-06 서울대학교 산학협력단 항-ros1 항체 및 그의 용도
CN108129288B (zh) * 2017-12-27 2021-01-22 上海毕得医药科技股份有限公司 一种反式-3-羟基环丁基甲酸的合成方法
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
CN111615514B (zh) 2018-01-18 2022-10-11 奥瑞生物药品公司 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
EP3773725A1 (en) 2018-03-29 2021-02-17 Loxo Oncology Inc. Treatment of trk-associated cancers
JP7174143B2 (ja) 2018-07-24 2022-11-17 大鵬薬品工業株式会社 Ｓｈｐ２活性を阻害するヘテロ二環性化合物
US12109193B2 (en) 2018-07-31 2024-10-08 Loxo Oncology Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide
EP3849986B1 (en) 2018-09-10 2022-06-08 Array Biopharma, Inc. Fused heterocyclic compounds as ret kinase inhibitors
EP3898615A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
WO2020131627A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
WO2020179859A1 (ja) * 2019-03-06 2020-09-10 第一三共株式会社 ピロロピラゾール誘導体
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
AU2020270303B2 (en) * 2019-05-08 2023-09-07 Tyk Medicines, Inc. Compound used as kinase inhibitor and application thereof
GB201911928D0 (en) 2019-08-20 2019-10-02 Otsuka Pharma Co Ltd Pharmaceutical compounds
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AR122159A1 (es) * 2020-05-28 2022-08-17 Novartis Ag Inhibidores de mll1 y agentes antineoplásicos
CN114957259A (zh) * 2021-02-25 2022-08-30 南京明德新药研发有限公司 氰基取代的芳香双环类化合物及其应用
AU2021453749A1 (en) * 2021-07-01 2023-12-21 Nuvation Bio Inc. Crystalline forms of 3-{4-[(2r)-2-aminopropoxy]phenyl}-n-[(1r)- 1-(3-fluorophenyl) ethyl]imidazo[1,2-b]pyridazin-6-amine and salts thereof
WO2023220967A1 (en) * 2022-05-18 2023-11-23 Anheart Therapeutics (Hangzhou) Co., Ltd. Method for producing 3,6-disubstituted-imidazo[1,2-b]pyridazine compounds
CN114989176B (zh) * 2022-07-08 2024-08-27 深圳市新樾生物科技有限公司 咪唑并哒嗪类衍生物及其应用
CN115197115B (zh) * 2022-08-25 2024-11-08 成都金博汇康医药科技有限公司 一种手性5-氧代吡咯烷-3-甲酸的制备方法与应用
CN117659020A (zh) * 2022-09-07 2024-03-08 苏州朗睿生物医药有限公司 一种咪唑并[1,2-b]哒嗪衍生物及其制备方法和用途
JP2025532532A (ja) * 2022-09-07 2025-10-01 蘇州朗睿生物医薬有限公司 大環状イミダゾ［１，２－ｂ］ピリダジン誘導体並びにその調製方法及び用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008052734A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
WO2008058126A2 (en) 2006-11-06 2008-05-15 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
WO2009140128A2 (en) 2008-05-13 2009-11-19 Irm Llc Compounds and compositions as kinase inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
AU2001288374A1 (en) 2000-09-01 2002-03-22 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
WO2002020513A1 (en) 2000-09-01 2002-03-14 Glaxo Group Limited Oxindole derivatives
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
EP1742921A2 (en) 2004-04-21 2007-01-17 AstraZeneca AB Pyrazole derivatives useful for the treatment of cancer
US20080167314A1 (en) 2004-12-28 2008-07-10 Osamu Uchikawa Condensed Imidazole Compound And Use Thereof
DK1846394T3 (da) 2005-02-04 2012-01-16 Astrazeneca Ab Pyrazolylaminopyridinderivater, der er egnede som kinaseinhibitorer
CA2598076A1 (en) 2005-02-16 2006-08-24 Astrazeneca Ab Chemical compounds
PT1853588E (pt) 2005-02-16 2008-08-25 Astrazeneca Ab Compostos químicos
JP2009502734A (ja) 2005-07-29 2009-01-29 アステラス製薬株式会社 Ｌｃｋ阻害剤としての縮合複素環
CN101208339B (zh) * 2005-08-01 2010-12-29 霍夫曼-拉罗奇有限公司 杂环苄基氨基衍生物，它们的制备以及作为药剂的应用
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102006029447A1 (de) * 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel
WO2008072682A1 (ja) * 2006-12-15 2008-06-19 Daiichi Sankyo Company, Limited イミダゾ［１，２－ｂ］ピリダジン誘導体
JP2009227599A (ja) * 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
PT2350075E (pt) * 2008-09-22 2014-06-09 Array Biopharma Inc Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase
KR101147550B1 (ko) * 2009-10-22 2012-05-17 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노［3,2-ｄ］피리미딘 화합물
WO2012005299A1 (ja) 2010-07-07 2012-01-12 日本新薬株式会社 Ｒｏｓチロシンキナーゼ阻害剤
WO2012125667A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008052734A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
WO2008058126A2 (en) 2006-11-06 2008-05-15 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
WO2009140128A2 (en) 2008-05-13 2009-11-19 Irm Llc Compounds and compositions as kinase inhibitors

Also Published As

Publication number Publication date
ZA201408843B (en) 2016-01-27
JPWO2013183578A1 (ja) 2016-01-28
NO2857404T3 (https=) 2018-01-20
EP2857404A1 (en) 2015-04-08
ES2648228T3 (es) 2017-12-29
US9187489B2 (en) 2015-11-17
US20150051190A1 (en) 2015-02-19
JP5814467B2 (ja) 2015-11-17
LT2857404T (lt) 2017-11-10
IL236075A (en) 2017-10-31
US20160046639A1 (en) 2016-02-18
HRP20171724T1 (hr) 2018-01-12
EP2857404B1 (en) 2017-08-23
RU2635917C2 (ru) 2017-11-17
HK1207374A1 (en) 2016-01-29
RU2014153627A (ru) 2016-08-10
EP2857404A4 (en) 2016-01-20
IN2014MN02497A (https=) 2015-07-17
HUE037221T2 (hu) 2018-08-28
CY1119607T1 (el) 2018-04-04
CN104520300A (zh) 2015-04-15
TW201400486A (zh) 2014-01-01
US9751887B2 (en) 2017-09-05
AU2013272701A1 (en) 2015-01-15
PT2857404T (pt) 2017-11-23
BR112014029851B1 (pt) 2023-01-03
PL2857404T3 (pl) 2018-04-30
NZ702574A (en) 2016-07-29
AU2013272701A2 (en) 2015-01-22
AU2013272701B2 (en) 2017-12-21
TWI585088B (zh) 2017-06-01
CO7160119A2 (es) 2015-01-15
PH12014502721B1 (en) 2015-02-02
SI2857404T1 (sl) 2017-11-30
CA2874819A1 (en) 2013-12-12
SG11201408052WA (en) 2015-01-29
CN104520300B (zh) 2016-12-21
MX2014014803A (es) 2015-02-12
SMT201700539T1 (it) 2018-01-11
BR112014029851A2 (pt) 2017-06-27
MX357021B (es) 2018-06-25
DK2857404T3 (en) 2017-12-04
KR20150014942A (ko) 2015-02-09
MY170326A (en) 2019-07-17
CA2874819C (en) 2017-06-20
WO2013183578A1 (ja) 2013-12-12
PH12014502721A1 (en) 2015-02-02
RS56625B1 (sr) 2018-03-30
IL236075A0 (en) 2015-02-01

Similar Documents

Publication Publication Date Title
KR101781255B1 (ko) 키나아제 저해제로서의 이미다조[1,2-b]피리다진 유도체
EP3865488A1 (en) Macrocyclic compound as cdk inhibitor, preparation method therefor, and use thereof in medicine
EA007298B1 (ru) Гетероариламины в качестве ингибиторов гликогенсинтаза-киназы 3-бета (ингибиторов gsk3)
TW200835485A (en) Novel aminopyrimidine derivatives as PLK1 inhibitors
EP3694331B1 (en) Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
KR20150104089A (ko) 치환된 인돌-5-올 유도체와 그들의 치료적 용도
CN112745298B (zh) 多取代异吲哚啉类化合物、其制备方法、药物组合物及用途
JP7584623B2 (ja) キナーゼ阻害活性を有する化合物
US12552785B2 (en) Pyrazolo[1,5-α]pyridine derivative, preparation method therefor, and composition and use thereof
CN113164481A (zh) 环烷-1,3-二胺衍生物
WO2020057669A1 (zh) 一类具有激酶抑制活性的芳香杂环类化合物
EP4308096A1 (en) Heteroaroyl amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
CN113563341B (zh) 作为Trk抑制剂的取代的吡唑并[1,5-a]嘧啶化合物
HK1207374B (en) Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
CN117820305A (zh) 杂环取代喹唑啉及其制备方法和应用
HK40082804A (en) Amide compounds and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141127

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160727

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20160727

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20161130

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20170731

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20170918

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20170918

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20200908

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20200908

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20210907

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20210907

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20220902

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20220902

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20230905

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20240823

Start annual number: 8

End annual number: 8